Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | USP5 | P45974 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.56 |
| ▸ | WNT3A | P56704 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL8467793 | 1.00 | KMT2A (1.00) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL16922187 | 1.00 | KMT2A (1.00) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL7857467 | 0.94 | KMT2A (0.89) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL16552778 | 0.91 | KMT2A (0.83) | KMT2ARAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL8467798 | 0.89 | KMT2A (0.79) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL10353454 | 0.89 | NR4A2 (0.81) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL5849125 | 0.88 | KMT2A (0.78) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL2743310 | 0.88 | KMT2A (0.78) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 | |
| SCHEMBL8269520 | 0.87 | KMT2A (0.77) | KMT2ANR4A2RAB9ASMN1; SMN2FFAR1 | |
| SCHEMBL6930410 | 0.86 | KMT2A (0.74) | KMT2ANR4A2USP5RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584034-B2 | Coating composition for forming a flexible dielectric coat with high dielectric permittivity | TRIBI Technologies d.o.o. (HR) | 2026-03-24 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250154372-A1 | COATING COMPOSITION FOR FORMING A FLEXIBLE DIELECTRIC COAT WITH HIGH DIELECTRIC PERMITTIVITY | YELLOW DOT D.O.O. (HR) | 2025-05-15 | — | — | US | claimed |
| CN-108752273-A | A kind of preparation method of Cinchonic Acid's derivative of 3- straight chained alkyls carboxyl substitution | 湖北欣瑞康医药科技有限公司 | 2018-11-06 | — | — | CN | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-7422649-B2 | Method for recording information in luminescent compositions and uses thereof in articles of manufacture | AMERICAN DYE SOURCE, INC. (CA) | 2008-09-09 | — | — | US | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| US-6921839-B2 | Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-26 | — | — | US | claimed |
| US-20040054230-A1 | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2004-03-18 | — | — | US | claimed |
| EP-1370515-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES, LTD. (IN) | 2003-12-17 | — | — | EP | claimed |
| WO-2002018303-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES LIMITED (IN) | 2002-03-07 | — | — | WO | claimed |
| JP-6321851-A | — | — | None | — | — | JP | disclosed |
| US-4058529-A | Polycyclic amino derivatives of pyrrolidone and piperidone | CIBA-GEIGY CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4052395-A | AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES | SANKYO COMPANY LIMITED (JA) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584034-B2 | Coating composition for forming a flexible dielectric coat with high dielectric permittivity | CACNA2D3, PLOD3, CACNA2D1 | KMT2A 4027/4885NR4A2 2190/4885USP5 2494/4885 |
| US-20040054230-A1 | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | GABRA4, GABRA3, GABRA6 | KMT2A 80/4885NR4A2 416/4885USP5 1540/4885 |
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | KMT2A 3434/4885NR4A2 4005/4885USP5 3327/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | KMT2A 4752/4885NR4A2 3782/4885USP5 1434/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | KMT2A 1376/4885NR4A2 738/4885USP5 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.